Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $1,909,500.00 in Stock

Posted by Brenda Bartman on Oct 2nd, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.46, for a total transaction of $1,909,500.00. Following the transaction, the chief executive officer directly owned 528,621 shares in the company, valued at $13,458,690.66. This trade represents a 12.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics Trading Down 0.4%

NASDAQ:MLYS traded down $0.09 on Friday, hitting $23.63. The stock had a trading volume of 927,285 shares, compared to its average volume of 1,283,460. The company has a fifty day moving average price of $26.95 and a two-hundred day moving average price of $27.02. Mineralys Therapeutics, Inc. has a 1-year low of $22.30 and a 1-year high of $47.65. The company has a quick ratio of 34.46, a current ratio of 34.46 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -5.57 and a beta of 0.69.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). Equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. KBC Group NV acquired a new stake in shares of Mineralys Therapeutics in the first quarter valued at $33,000. Caitong International Asset Management Co. Ltd raised its position in Mineralys Therapeutics by 1,845.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after purchasing an additional 1,993 shares in the last quarter. FNY Investment Advisers LLC boosted its stake in shares of Mineralys Therapeutics by 400.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock valued at $67,000 after buying an additional 2,000 shares during the period. Quantinno Capital Management LP grew its position in shares of Mineralys Therapeutics by 12.6% during the first quarter. Quantinno Capital Management LP now owns 20,541 shares of the company’s stock worth $556,000 after buying an additional 2,298 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of Mineralys Therapeutics by 22.4% during the second quarter. Arizona State Retirement System now owns 15,357 shares of the company’s stock worth $414,000 after buying an additional 2,815 shares in the last quarter. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MLYS shares. Wall Street Zen cut Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Finally, Zacks Research upgraded Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $48.80.

Check Out Our Latest Analysis on MLYS

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and other cardiovascular and kidney-related conditions associated with excess aldosterone activity. The company is headquartered in Radnor, Pennsylvania.

Mineralys’ lead product candidate is lorundrostat, an oral, highly selective aldosterone synthase inhibitor designed to reduce the production of aldosterone. The company is evaluating lorundrostat as a potential treatment for uncontrolled or resistant hypertension, including hypertension linked to abnormal activation of the renin-angiotensin-aldosterone system.

Mineralys was established to advance therapies targeting aldosterone-driven disease and became a publicly traded company on the Nasdaq exchange in 2023.